Navigare Ventures

IntuiCell develops a fundamentally new recursive computing architecture and associated technology platform.

Repli5 is a company focused on accelerating and reducing the costs associated with the development of autonomous vehicles. It has developed a software tool that simplifies the creation of virtual three-dimensional environments, which are essential for the automated testing and development of autonomous systems. By automating the generation of these multi-dimensional simulation environments, Repli5 enables faster and more customized vehicle development. This innovative approach provides the automotive industry with the capability to expedite the integration of advanced mobility solutions into current operations, enhancing both freight and haulage processes.

SweGaN specializes in the development of custom-made epitaxial wafers, focusing on gallium nitride (GaN) structures integrated on silicon carbide (SiC) substrates. The company's technology aims to enhance the performance of high-power and high-frequency devices, particularly in applications such as military radar and energy-efficient mobile base stations. By utilizing GaN on SiC, SweGaN's products contribute to reduced energy consumption while increasing capacity, allowing clients to meet the demands of modern technology. Founded by experts from Linköping University, the company boasts extensive experience in the growth and characterization of semiconductor materials and is currently in an expansive phase, seeking skilled individuals to join their team.

Arevo offers liquid and granular amino acid fertilizer technologies for faster and better plant establishment.

RiACT develops robotic automation software aimed at enhancing agile production systems. The company's platform serves as a universal operating system for industrial robots, facilitating the connection between robotic hardware and intelligent applications. It features a real-time development environment that offers a visual drag-and-drop interface and template-based coding, making it accessible for creators and users of flexible robot applications. By streamlining the interaction between robots and their applications, RiACT aims to boost human potential and overall productivity in industrial settings.

Pixelgen Technologies is a company focused on advancing biomedical research and diagnostics through the development of innovative bio-analytical tools. Founded in 2020 and based in Sweden, the firm specializes in creating novel analytical methods and products that enhance the understanding of biological processes. These tools are designed to provide researchers and drug developers with valuable insights into biomedicine, ultimately aiming to improve health outcomes. By delivering advanced solutions for biomedical analysis, Pixelgen Technologies plays a crucial role in supporting scientific discovery and development in the healthcare sector.

AlixLabs specializes in nanostructure fabrication using atomic layer etching (ALE) technology. This innovative approach enables the production of nanostructures with sizes less than 20 nanometers, surpassing the limitations of traditional optical and electron beam lithography. By employing a damage-free etching process, AlixLabs facilitates the manufacturing of extremely small structures with high precision and efficiency, which is particularly beneficial for the semiconductor industry. The company's methods may also support the economically viable scaling of transistor channels for sub-20 nanometer technology nodes, positioning AlixLabs as a key player in advancing nanoelectronics.

We develop hardware solutions that offer best-in-class performance, size and weight by combining scalable manufacturing and cutting-edge design techniques. Our groundbreaking system-in-package (SiP) technology merges ultra-low loss, pinpoint precision, and featherlight design into one powerhouse solution. This innovation enables us to engineer RF systems that deliver an unmatched combination of compactness, lightness, and high performance – redefining the future of wireless technology and outperforming conventional SoCs.

Retein is a water purification technology company focused on producing pure water at a low energy cost. Utilizing advanced materials and aquaporin proteins, Retein's technology effectively removes pollutants, including microplastics and pharmaceutical residues, from water. This innovative approach not only ensures the sustainable recovery of valuable resources but also promotes efficiency and cost-effectiveness for clients. By advancing water purification methods, Retein contributes to a resource-efficient and sustainable future.

AlixLabs specializes in nanostructure fabrication using atomic layer etching (ALE) technology. This innovative approach enables the production of nanostructures with sizes less than 20 nanometers, surpassing the limitations of traditional optical and electron beam lithography. By employing a damage-free etching process, AlixLabs facilitates the manufacturing of extremely small structures with high precision and efficiency, which is particularly beneficial for the semiconductor industry. The company's methods may also support the economically viable scaling of transistor channels for sub-20 nanometer technology nodes, positioning AlixLabs as a key player in advancing nanoelectronics.

EnginZyme AB is a biotechnology company based in Stockholm, Sweden, founded in 2014. The company specializes in biocatalysis and a cell-free synthetic biology platform to create sustainable alternatives to conventional materials such as plastics, nylons, and rubbers. EnginZyme's innovative approach focuses on biomanufacturing techniques that promote green chemistry across various industries, including pharmaceuticals, food, chemicals, flavors, and fragrances. By utilizing patented cell-free technology, EnginZyme aims to replace traditional fossil-based manufacturing, thus facilitating the shift toward environmentally friendly production methods. The company has gained recognition for its contributions to sustainability, being named a Global Cleantech 100 company and recognized as a Technology Pioneer by the World Economic Forum. EnginZyme is supported by a diverse group of investors, reflecting its potential impact on addressing climate change and promoting sustainable practices in manufacturing.

Pixelgen Technologies is a company focused on advancing biomedical research and diagnostics through the development of innovative bio-analytical tools. Founded in 2020 and based in Sweden, the firm specializes in creating novel analytical methods and products that enhance the understanding of biological processes. These tools are designed to provide researchers and drug developers with valuable insights into biomedicine, ultimately aiming to improve health outcomes. By delivering advanced solutions for biomedical analysis, Pixelgen Technologies plays a crucial role in supporting scientific discovery and development in the healthcare sector.

Rarity Bioscience specializes in developing advanced molecular amplification technology for the detection of nucleic acid sequences in biological samples, particularly in liquid biopsies. The company offers an ultrasensitive multiplex assay that enables the identification of rare DNA sequence variants. This innovative platform serves both research and clinical applications, providing physicians with valuable tools for accurate diagnostics and improved patient care.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Repli5 is a company focused on accelerating and reducing the costs associated with the development of autonomous vehicles. It has developed a software tool that simplifies the creation of virtual three-dimensional environments, which are essential for the automated testing and development of autonomous systems. By automating the generation of these multi-dimensional simulation environments, Repli5 enables faster and more customized vehicle development. This innovative approach provides the automotive industry with the capability to expedite the integration of advanced mobility solutions into current operations, enhancing both freight and haulage processes.

Peafowl Plasmonics specializes in innovative solar cell technology that is highly transparent, efficient, and sustainable. The company has developed plasmonic solar cells capable of absorbing light in various conditions, whether in harsh outdoor environments or low-illumination indoor settings. This technology not only enhances energy efficiency but also allows for the direct integration of sensors into window glass without the need for wires or batteries. By enabling commercial partners and customers to reduce energy consumption and carbon emissions, Peafowl Plasmonics actively contributes to lowering corporate carbon footprints and promoting sustainable energy solutions.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, specializing in the development of a metabolism-based liquid biopsy platform aimed at the early detection and monitoring of cancer. Founded in 2017, the company focuses on measuring biomarkers in blood and urine, employing machine learning and artificial intelligence algorithms to identify cancer signatures. Elypta is actively conducting the AURORAX clinical trial series to explore applications for its platform, particularly in renal cell carcinoma, while also investigating other cancer indications. The technology includes a new in vitro diagnostic laboratory assay kit, which enables comprehensive profiling of glycosaminoglycan metabolites and supports a range of applications from screening to treatment response monitoring, facilitating earlier interventions in cancer care.